Sign In
Sign Out
My Account
Subscribe
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
Special reports
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
See today's BioWorld
Home
» Regulatory submissions, approvals and other actions: January 2020
To read the full story,
subscribe
or
sign in
.
Regulatory submissions, approvals and other actions: January 2020
Feb. 14, 2020
Regulatory decisions affecting biopharma products in development, including: Abbvie, Aimmune, Alkermes, Alnylam, Amarin, Biohaven, Biolinerx, Blueberry, Clovis, Cytodyn, Durect, Emergent, Evoke, Exelixis, Fate, F-star, Galapagos, Genmab, Horizon, Incyte, Ipsen, Janssen, Jubilant, Mesoblast, Nabriva, Nektar, Nicox, Orion, Pharmacyte, Pharming, Pulmatrix, Recordati, Regeneron, Seelos, Sorrento, Ultragenyx, Vistagen.
BioWorld
Analysis and data insight
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe